$DYN News

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Why Dyne Therapeutics (DYN) Is Back In The Spotlight

HC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Lowers Price Target to $32

Dyne Therapeutics stock rises on positive DM1 trial results

Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)

Dyne Therapeutics Announces Additional One-Year Clinical Data From Phase 1/2 ACHIEVE Trial

Piper Sandler Reiterates Overweight on Dyne Therapeutics, Maintains $47 Price Target

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Do Dyne Therapeutics’ (DYN) Expanded DM1 Data Presentations Redefine Its Rare-Disease Investment Narrative?

Dyne Therapeutics, Inc. (DYN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $36

RBC Capital Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $30

Baird Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $26

Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings

Dyne Therapeutics Shares Fall 31% Premarket With No Catalyst Confirmed

Dyne Therapeutics To Demonstrate Additional One-Year Results From Phase 1/2 ACHIEVE Study Of Zeleciment Basivarsen For DM1 At Annual International Congress Of World Muscle Society

Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting

Dyne Therapeutics to Participate in Upcoming Investor Conferences

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $45